PTPRZ1 and neoplasm: Disruption of PTN–PTPRZ1 signalling potently inhibits GSC-driven tumour growth, indicating that therapeutic targeting of PTN–PTPRZ1 signalling may effectively improve treatment for GBMs and potentially other malignant tumours.